Symrise (SY1) Q3 2026 TU earnings summary

Executive summary

• Q3 organic sales growth reached 5.3%, predominantly volume-driven, with both segments contributing and more favorable year-over-year comparables.

• Asia Pacific led regional growth, supported by strong Latin American and solid North American performance; EAME growth was moderate.

Financial highlights

• Q3 reported sales were €1,310.4m versus €1,222.5m; organic growth was 5.3%, comprising 6.1% volume growth and 0.8% negative pricing.

• Q3 portfolio impact was -0.5% and FX contribution was 2.3%; 9M sales were €3,849.8m versus €3,776.2m, with 3.0% organic growth.

• Terpenes generated approximately €130m in annual sales; its portfolio impact will occur in two stages and extend beyond the usual 12-month period.

Outlook and guidance

• FY 2026 guidance reaffirmed: organic sales growth of 2%–4%, adjusted EBITDA margin of 21.5%–22.5%, and adjusted business free cash flow margin above 14%.

• Full-year organic growth is expected near the guidance midpoint; adjusted EBITDA margin is expected in the lower half, reflecting investment in IT, innovation and capabilities.

• Q4 organic growth is expected to moderate sequentially below Q3 against higher comparables; midterm targets remain unchanged.

• 2025–2028 targets are 5%–7% organic sales CAGR, 21%–23% EBITDA margin and above 14% BFCF margin.